Poor progression-free survival

Author: vfap

August undefined, 2024

WebNov 17, 2016 · SNAP23 is hyper-expressed in OC tumor tissues compared to normal tissues, and increased expression of SNAP23 is associated with a poor progression free survival (HR = 1.24, 95% CI = 1.07–1.44, p = 0.0042). SNAP23 knock down increases cell apoptosis and inhibits cell proliferation, migration and invasion of OC cells.

A nomogram model based on pre-treatment and post-treatment …

WebApr 9, 2024 · Overall survival (OS) and progression-free survival (PFS) were evaluated using the Kaplan–Meier method with a log-rank test. The cumulative incidence of locoregional … WebConclusion: Our data indicate that the PIK3CA mutations H1047R and H1047L are significant genetic alterations in lung adenocarcinoma. Among lung adenocarcinoma patients who underwent curative resection, PIK3CA mutations were associated with shorter progression-free survival. Our findings demonstrated a significant role of PIK3CA in lung ... simon murphy decipher

Understanding Cancer Prognosis - NCI - National Cancer Institute

WebProgression-free survival refers to the time from randomisation or initiation of treatment to the occurrence of disease progression or death. Disease progression is defined by the Response Evaluation Criteria in Solid Tumors as an increase in the sum of maximum … WebSep 27, 2024 · It is associated with rapid disease progression and a shorter progression free survival. ... which results in the loss of TP53, is the most important prognostic marker in CLL and is associated with poor outcomes, rapid disease progression and is historically associated with resistance to standard fludarabine-based chemoimmunotherapy. WebWe investigated the relationship between progression-free survival (PFS) and patient characteristics. Results: In both univariate and multivariate analysis, performance status … simon murphy real estate

Progression-Free Survival: What Does It Mean for Psychological Well

Progression Free Survival - an overview ScienceDirect Topics

WebApr 20, 2024 · Approximately 31% of patients diagnosed with multiple myeloma (MM) have pre-existing hypertension, but its effects on patient survival have not been investigated. … WebProgression-free survival (PFS) is "the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse". In … simon murphy unswWebApr 6, 2024 · miR-25 overexpression in CD138+ plasma cells is associated with poor overall and progression-free survival. Kaplan–Meier survival curves for A overall survival (OS) and B progression-free survival (PFS) of the screening cohort, and for C OS of the MMRF CoMMpass validation cohort, according to CD138+ miR-25 expression. simon murray ewr

"WebImmunohistochemistry revealed 11 p53-positive cases among 53 patients with mRCC. Kaplan-Meier analysis showed that p53-positive cases tended to be associated with poor … " - Poor progression-free survival

Poor progression-free survival

Risk Factors Associated with Durable Progression-Free Survival in ...

WebNov 12, 2024 · Progression-free survival (PFS) was defined according to revised National Cancer Institute criteria. Imaging evaluation was performed on each patient at TT. TMTV, evaluated on 18 FDG-PET, and tumor bulk, measured on CT, were analyzed at TT, after the last bridging treatment, if any, and before starting the lymphodepletion therapy. WebNivolumab, an anti–programmed death 1 antibody, has been approved for the treatment of NSCLC. Although nivolumab improves overall survival (OS) more than docetaxel when …

Did you know?

WebJun 23, 2014 · Conclusions. Progression-free survival is expectedly poor for patients with BRAF-mutated metastatic colorectal cancer.Despite the ascertainment bias present (with … Webprogression-free survival: , PFS In cancer care, the time during which a patient shows no signs or symptoms of the growth or the spreading of a tumor.

WebApr 7, 2024 · A Progression-free survival and B overall survival in DLBCL patients with low, medium, or high normalized levels of surface TREM2 on M-MDSCs. Normalized MFI changes of surface TREM2 on M-MDSCs being grouped into < 2%, 2–44%, and > 44%; cut-off values for normalized MFI changes of surface TREM2 determined by ROC analysis and AUC. WebApr 11, 2024 · To establish a novel model using radiomics analysis of pre-treatment and post-treatment magnetic resonance (MR) images for prediction of progression-free …

WebDec 1, 2024 · The 1-year overall survival and progression-free survival rates were 78.0% and 50.2%, respectively. Furthermore, we identified extramedullary disease, light chain multiple myeloma, and certain high-risk cytogenetic factors as important independent predictors of a poor prognosis in those receiving anti-BCMA CAR T-cell therapy. WebMethods Forty-three nasopharyngeal carcinoma patients less than 19 years old were recruited between April 2010 and April 2016. All patients were treated with IMRT (total dose 61.2-76 Gy) combined with cisplatin based chemotherapy. The Kaplan-Meier test was used to calculate overall survival (OS) and progression-free survival (PFS).

WebThe aim of the present study was to identify clusters of metabolic heterogeneity, using a large MRSI dataset, and determine which of these clusters are predictive of progression …

WebNational Center for Biotechnology Information simon murphy physioWebThe patients were divided into high and low sIL-2R groups based on the median of sIL-2R levels at pretreatment. Progression-free survival (PFS) and overall survival (OS) of patients in the high and low sIL-2R groups were compared. The Kaplan–Meier curves of PFS and OS were evaluated using the log-rank test. simon murray french foreign legionWebWe investigated the relationship between progression-free survival (PFS) and patient characteristics and analyzed predictive factors associated with good PS (PS 0-1) or poor … simon murray national trustWebPD-1 blockade monotherapy yielded an objective response rate (ORR) of approximately 20%, a median progression-free survival (PFS) of 3-6 months, and a median overall survival (OS) of 10-15 months ... simon murphy worcesterWebJan 1, 2024 · Kaplan-Meier analysis for progression-free survival according to CRP in (A) whole study population, (B) melanoma patients, (C) NSCLC patients and (D) GU cancer … simon murphys flying circusWebApr 9, 2024 · Non-small cell cancer (NSCLC) has been identified with a great variation of mutations that can be surveyed during disease progression. The aim of the study was to identify and monitor lung cancer-specific mutations incidence in cell-free DNA as well as overall plasma cell-free DNA load by means of targeted next-generation sequencing. … simon muys gilbert tobinWebFeb 1, 2012 · In general, correlations between PFS and OS were poor to moderate regardless of the cut-off used. Download : Download high-res image (61KB) Download : Download … simon murray uk government